Digestery
Longevity supplements › Resveratrol and Aging › Studies

Randomized trial · measured lab tests or safety

12-week trial in 41 older adults: resveratrol did not change a heart risk marker

Baptista and colleagues · Experimental gerontology · 2024

Original title: Effects of resveratrol on changes in trimethylamine-N-oxide and circulating cardiovascular factors following exercise training among older adults.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

No difference

A gut-made heart risk marker (TMAO) rose over time in all groups, regardless of treatment (p = 0.04). Resveratrol changed other blood chemicals in a dose-dependent way, but not TMAO.

The study at a glance

Type of study
Randomized trial
Who or what was studied
41 people · Older adults (average age 72.1) at high risk of heart disease
What was tested
Resveratrol 500 or 1000 mg a day vs placebo, plus 12 weeks of group exercise
What it measured
Lab tests or markers
Daily amount
1000 mg a day
How long
12 weeks
Who has a stake
No stake declared
No competing interests declared.
Journal
Experimental gerontology, 2024
Source
PubMed record 38871236. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • –Small: 41 people. Small trials can miss real effects or find chance ones.
  • •Lasted 12 weeks.
  • –Measured lab tests or markers, which stand in for aging and age-related disease. A better marker does not always mean better health.
  • ✓No competing interests declared.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    3

    1 benefit, 1 mixed, 1 no difference

  2. Trials in people: other measures

    3

    1 benefit, 1 mixed, 1 harm

  3. Trials in people: lab tests or safety

    7

    4 benefit, 2 mixed, 1 no difference

    ↑ This study is the ringed dot

  4. Population studies

    1

    1 benefit

  5. Blood levels and genes

    1

    1 no difference

  6. Animals

    1

    1 benefit

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does resveratrol slow aging?”

Not shown in people.

Confidence: very low. Based on 22 on-topic papers.

Read the full answer

Of the other 6 papers on the same step: 4 benefit, 2 mixed. This one found no difference. It differs from most of them.

Other papers on the same step

See all 22 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The reviewer corrected 1 field after reading the abstract. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.